This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Prolact+ H2MF (Prolacta Bioscience Inc.) human milk-derived human milk fortifier (HMF) for infants with very low birth weight (VLBW) to support healthy weight gain and help reduce gastrointestinal complications while in the neonatal intensive care unit (NICU).
